| Autor: |
Campregher PV; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Mattos VRP; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Salvino MA; Hospital São Rafael, Salvador, BA, Brazil., Santos FPS; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Hamerschlak N; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. |
| Jazyk: |
English; Portuguese |
| Zdroj: |
Einstein (Sao Paulo, Brazil) [Einstein (Sao Paulo)] 2017 Jul-Sep; Vol. 15 (3), pp. 355-358. Date of Electronic Publication: 2017 Jul 24. |
| DOI: |
10.1590/S1679-45082017RC3784 |
| Abstrakt: |
Acute myeloid leukemia is a hematopoietic stem cell neoplastic disease associated with high morbidity and mortality. The presence of FLT3 internal tandem duplication mutations leads to high rates of relapse and decreased overall survival. Patients with FLT3 internal tandem duplication are normally treated with hematopoietic stem cell transplantation in first complete remission. Nevertheless, the incidence of post-transplant relapse is considerable in this group of patients, and the management of this clinical condition is challenging. The report describes the outcomes of patients with FLT3 internal tandem duplication positive acute myeloid leukemia who relapsed after allogeneic hematopoietic stem cell transplantation and were treated with the combination of re-induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Three cases are described and all patients achieved prolonged complete remission with the combined therapy. The combination of induction chemotherapy followed by donor lymphocyte infusion, and the maintenance with azacitidine and sorafenib can be effective approaches in the treatment of post-hematopoietic stem cell transplant and relapsed FLT3 internal tandem duplication positive acute myeloid leukemia patients. This strategy should be further explored in the context of clinical trials. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
